Rvx208, a new cardiovascular and cerebrovascular drug, is preparing for the third phase of clinical application

On the interactive platform, Highbury (002399 SZ) said that rvx208 is actively preparing for phase III clinical Insiders of the company said that this product is for the treatment of coronary arteriosclerosis New cardiovascular drugs generally have a wide market, and the company is optimistic about the prospect of new drugs Rvx208 is a new product being developed by resverlogix Corp (hereinafter referred to as "RVx") Last month, HPRI announced that it would use its own capital of 35.4309 million yuan to subscribe for 13.27 million newly issued shares of RVx, and RVx granted 1000000 warrants to HPRI The investment is still in progress and the drug still needs to be approved by the FDA, the person said It's hard to say the specific market space It is understood that RVx is a new drug R & D company that develops drugs for the treatment of cardiovascular and cerebrovascular diseases It is committed to the development of small molecule drugs that selectively inhibit bromine domain and extra terminal domain proteins Currently, rvx208 is being developed, which has basically completed the second phase of clinical practice and is about to enter the third phase of clinical practice Industry insiders said that they are optimistic about the business transformation of hipre, and investment in RVx may be a direction for the company's transformation The product heparin sodium API of Shenzhen hiprui Pharmaceutical Co., Ltd is exported to the world Its customers include world-famous multinational pharmaceutical enterprises, such as Sanofi Aventis, Fresenius kabi, Novartis, etc Hiprec was founded in 1998 and restructured into a joint stock limited company in 2007 It was listed on the Shenzhen Stock Exchange on May 6, 2010 The securities are referred to as "hiprec" for short and the securities code is "002399" With a registered capital of 800.2 million yuan, the company is headquartered in the beautiful Shenzhen high tech park.